{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:22:10Z","timestamp":1793884930536,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Frailty is a marker of poor prognosis in older adults with hematologic malignancies and contributes to the severe vulnerability of the aging population to adverse health outcomes. This study aimed to determine the association between frailty and outcomes in hospitalized patients with chronic myeloid leukemia (CML).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The International Classification of Diseases (ICD-10) identified data on hospitalized patients 20\u00a0years or older admitted with CML between 2016 and 2018 in the US National Inpatient Sample (NIS) database. The cohort was further divided into groups of patients with or without frailty. Logistic regression analysis was performed to determine associations between study variables and clinical outcomes. A stratified analysis of the association between frailty and in-hospital mortality by age group was also performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 13,849 hospitalized patients with CML were included, 49.6% of whom had frailty. The mean age of the patients was 65.1\u00a0years, and 7,619 (56.2%) of them were male. Frailty was associated with nearly 4 times the risk of in-hospital mortality, 3 times the risk of unfavorable discharge, 3 times the risk of prolonged LOS,, and significantly more in total hospital costs. In addition, frailty was associated with a significantly increased risk of in-hospital mortality in all age subgroups (&lt;\u200940\u00a0years, 40\u201359\u00a0years, and\u2009&gt;\u200960\u00a0years) compared with no frailty.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Frailty strongly predicts poor clinical outcomes in US patients with CML.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12877-023-03962-7","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:02:32Z","timestamp":1685433752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Frailty in chronic myeloid leukemia: evidence from 2016\u20132018 Nationwide Inpatient Sample of the US"],"prefix":"10.1186","volume":"23","author":[{"given":"Lin","family":"Huan-Tze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yun-Ru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Kuan-Der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzeng","family":"Huey-En","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"3962_CR1","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684\u201392.","journal-title":"Br J Cancer"},{"key":"3962_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11899-018-0454-x","volume":"13","author":"TT Koll","year":"2018","unstructured":"Koll TT, Rosko AE. Frailty in Hematologic Malignancy. Curr Hematol Malig Rep. 2018;13:143\u201354.","journal-title":"Curr Hematol Malig Rep"},{"key":"3962_CR3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.seminoncol.2020.02.010","volume":"47","author":"SA Graf","year":"2020","unstructured":"Graf SA, Samples LS, Keating TM, Garcia JM. Clinical research in older adults with hematologic malignancies: Opportunities for alignment in the Veterans Affairs. Semin Oncol. 2020;47:94\u2013101.","journal-title":"Semin Oncol"},{"key":"3962_CR4","doi-asserted-by":"publisher","first-page":"100670","DOI":"10.1016\/j.blre.2020.100670","volume":"43","author":"B Kanapuru","year":"2020","unstructured":"Kanapuru B, Singh H, Kwitkowski V, Blumenthal G, Farrell AT, Pazdur R. Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation. Blood Rev. 2020;43:100670.","journal-title":"Blood Rev"},{"key":"3962_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12603-020-1518-x","volume":"24","author":"D Angioni","year":"2020","unstructured":"Angioni D, Macaron T, Takeda C, Sourdet S, Cesari M, Virecoulon Giudici K, et al. Can we distinguish age-related frailty from frailty related to diseases? Data from the MAPT study. J Nutr Health Aging. 2020;24:1144\u201351.","journal-title":"J Nutr Health Aging"},{"key":"3962_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12603-019-1293-8","volume":"24","author":"K El Haddad","year":"2020","unstructured":"El Haddad K, Rolland Y, G\u00e9rard S, Mourey L, Sourdet S, Vellas B, et al. No difference in the phenotypic expression of frailty among elderly patients recently diagnosed with cancer vs cancer free patients. J Nutr Health Aging. 2020;24:147\u201351.","journal-title":"J Nutr Health Aging"},{"key":"3962_CR7","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1111\/jgs.13819","volume":"63","author":"JC Brown","year":"2015","unstructured":"Brown JC, Harhay MO, Harhay MN. The prognostic importance of frailty in cancer survivors. J Am Geriatr Soc. 2015;63:2538\u201343.","journal-title":"J Am Geriatr Soc"},{"key":"3962_CR8","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","volume":"23","author":"CA Bellera","year":"2012","unstructured":"Bellera CA, Rainfray M, Mathoulin-P\u00e9lissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166\u201372.","journal-title":"Ann Oncol"},{"key":"3962_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jgo.2013.04.003","volume":"4","author":"F Marchesi","year":"2013","unstructured":"Marchesi F, Cenfra N, Altomare L, Dessanti ML, Mecarocci S, Cerchiara E, et al. A retrospective study on 73 elderly patients (>=75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment. J Geriatr Oncol. 2013;4:242\u20138.","journal-title":"J Geriatr Oncol"},{"key":"3962_CR10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2017-09-746420","volume":"131","author":"GA Abel","year":"2018","unstructured":"Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018;131:515\u201324.","journal-title":"Blood"},{"key":"3962_CR11","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","volume":"105","author":"ERM Scheepers","year":"2020","unstructured":"Scheepers ERM, Vondeling AM, Thielen N, van der Griend R, Stauder R, Hamaker ME. Geriatric assessment in older patients with a hematologic malignancy: a systematic review. Haematologica. 2020;105:1484\u201393.","journal-title":"Haematologica"},{"key":"3962_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3324\/haematol.2012.067892","volume":"98","author":"B Deschler","year":"2013","unstructured":"Deschler B, Ihorst G, Platzbecker U, Germing U, M\u00e4rz E, de Figuerido M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98:208\u201316.","journal-title":"Haematologica"},{"key":"3962_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjh.14033","volume":"174","author":"R Buckstein","year":"2016","unstructured":"Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, et al. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016;174:88\u2013101.","journal-title":"Br J Haematol"},{"key":"3962_CR14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3109\/10428194.2014.953142","volume":"56","author":"A Tucci","year":"2015","unstructured":"Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma. 2015;56:921\u20136.","journal-title":"Leuk Lymphoma"},{"key":"3962_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/ejh.12608","volume":"96","author":"M Yoshida","year":"2016","unstructured":"Yoshida M, Nakao T, Horiuchi M, Ueda H, Hagihara K, Kanashima H, et al. Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for \u201cunfit\u201d patients classified by comprehensive geriatric assessment. Eur J Haematol. 2016;96:409\u201316.","journal-title":"Eur J Haematol"},{"key":"3962_CR16","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","volume":"99","author":"LS Muffly","year":"2014","unstructured":"Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99:1373\u20139.","journal-title":"Haematologica"},{"key":"3962_CR17","unstructured":"HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2012. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov\/nisoverview.jsp."},{"key":"3962_CR18","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","volume":"391","author":"T Gilbert","year":"2018","unstructured":"Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018;391:1775\u201382.","journal-title":"Lancet"},{"key":"3962_CR19","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/ageing\/afab073","volume":"50","author":"S Nghiem","year":"2021","unstructured":"Nghiem S, Afoakwah C, Scuffham P, Byrnes J. Hospital frailty risk score and adverse health outcomes: evidence from longitudinal record linkage cardiac data. Age Ageing. 2021;50:1778\u201384.","journal-title":"Age Ageing"},{"key":"3962_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/aas.13837","volume":"65","author":"GM Gunnarsdottir","year":"2021","unstructured":"Gunnarsdottir GM, Helgadottir S, Einarsson SG, Hreinsson K, Whittle J, Karason S, et al. Validation of the Hospital Frailty Risk Score in older surgical patients: A population-based retrospective cohort study. Acta Anaesthesiol Scand. 2021;65:1033\u201342.","journal-title":"Acta Anaesthesiol Scand"},{"key":"3962_CR21","doi-asserted-by":"publisher","first-page":"afab126","DOI":"10.1093\/ageing\/afab126","volume":"51","author":"T Gilbert","year":"2022","unstructured":"Gilbert T, Cordier Q, Polazzi S, Bonnefoy M, Keeble E, Street A, et al. External validation of the Hospital Frailty Risk Score in France. Age Ageing. 2022;51:afab126.","journal-title":"Age Ageing"},{"key":"3962_CR22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/annonc\/mdu540","volume":"26","author":"C Handforth","year":"2015","unstructured":"Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol. 2015;26:1091\u2013101.","journal-title":"Ann Oncol"},{"key":"3962_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/apjon.apjon_35_18","volume":"6","author":"E Atakul","year":"2019","unstructured":"Atakul E, Akyar \u0130. Frailty prevalence and characteristics in older adults with hematologic cancer: a descriptive study. Asia Pac J Oncol Nurs. 2019;6:43\u20139.","journal-title":"Asia Pac J Oncol Nurs"},{"key":"3962_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/CCI.19.00094","volume":"4","author":"BG Patel","year":"2020","unstructured":"Patel BG, Luo S, Wildes TM, Sanfilippo KM. Frailty in older adults with multiple myeloma: a study of US veterans. JCO Clin Cancer Inform. 2020;4:117\u201327.","journal-title":"JCO Clin Cancer Inform"},{"key":"3962_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34:224\u201333.","journal-title":"Leukemia"},{"key":"3962_CR26","doi-asserted-by":"crossref","unstructured":"Henderson TO, Ness KK, Cohen HJ. Accelerated aging among cancer survivors: from pediatrics to geriatrics. Am Soc Clin Oncol Educ Book 2014;34:e423\u201330.","DOI":"10.14694\/EdBook_AM.2014.34.e423"},{"key":"3962_CR27","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1016\/S2666-7568(21)00184-7","volume":"11","author":"V Goede","year":"2021","unstructured":"Goede V. Frailty assessment in the care of older people with haematological malignancies. Lancet Healthy Longevity. 2021;11:e736\u201345.","journal-title":"Lancet Healthy Longevity"},{"key":"3962_CR28","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jamaoncol.2016.0855","volume":"2","author":"M Arora","year":"2016","unstructured":"Arora M, Sun CL, Ness KK, Teh JB, Wu J, Francisco L, et al. Physiologic frailty in nonelderly hematopoietic cell transplantation patients: results from the bone marrow transplant survivor study. JAMA Oncol. 2016;2:1277\u201386.","journal-title":"JAMA Oncol"},{"key":"3962_CR29","doi-asserted-by":"publisher","first-page":"172641","DOI":"10.1016\/j.ejphar.2019.172641","volume":"862","author":"A Shimada","year":"2019","unstructured":"Shimada A. Hematological malignancies and molecular targeting therapy. Eur J Pharmacol. 2019;862:172641.","journal-title":"Eur J Pharmacol"},{"key":"3962_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","volume":"32","author":"BC Medeiros","year":"2018","unstructured":"Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Rev. 2018;32:289\u201399.","journal-title":"Blood Rev"},{"issue":"1","key":"3962_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/1759-7714.12545","volume":"9","author":"K Kakinuma","year":"2018","unstructured":"Kakinuma K, Tsuruoka H, Morikawa K, Furuya N, Inoue T, Miyazawa T, et al. Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer. Thorac Cancer. 2018;9(1):99\u2013104.","journal-title":"Thorac Cancer"},{"key":"3962_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000503829","volume":"9","author":"S Uchikawa","year":"2020","unstructured":"Uchikawa S, Kawaoka T, Namba M, Kodama K, Ohya K, Morio K, et al. Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. Liver Cancer. 2020;9:148\u201355.","journal-title":"Liver Cancer"},{"key":"3962_CR33","doi-asserted-by":"crossref","unstructured":"Elsamadicy AA, Koo AB, Reeves BC, Pennington Z, Sarkozy M, Hersh A, et al. Hospital Frailty Risk Score and healthcare resource utilization after surgery for primary spinal intradural\/cord tumors. Global Spine J. 2022;0:21925682211069937.","DOI":"10.1177\/21925682211069937"},{"key":"3962_CR34","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3390\/biomedicines9111693","volume":"9","author":"D Ramai","year":"2021","unstructured":"Ramai D, Dang-Ho KP, Kewalramani A, Bandaru P, Sacco R, Giacomelli L, et al. Hospital frailty risk score is independently associated with mortality and encephalopathy in hospitalized patients with hepatocellular carcinoma. Biomedicines. 2021;9:1693.","journal-title":"Biomedicines"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-023-03962-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-023-03962-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-023-03962-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:03:41Z","timestamp":1685433821000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-023-03962-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3962"],"URL":"https:\/\/doi.org\/10.1186\/s12877-023-03962-7","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"25 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data were obtained from the Online HCUP Central Distributor (), which administers the database (certificate # HCUP-4T39K81HZ). This study conforms to the NIS data-use agreement with HCUP. Because this study analyzed, secondary data from the NIS database, patients and the public were not involved directly. The protocol of this study was submitted to and exempted from the Institutional Review Board (IRB) of our Hospital. Due to all data in the NIS database are de-identified, informed consent was also waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"334"}}